Company Description
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level.
The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services.
The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services.
It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies.
The company has a strategic collaboration with HealthCore, Inc.
The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017.
IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Country | United States |
IPO Date | May 9, 2013 |
Industry | Medical - Diagnostics & Research |
Sector | Healthcare |
Employees | 88,000 |
CEO | Ari Bousbib |
Contact Details
Address: 4820 Emperor boulevard Durham, North Carolina United States | |
Website | https://www.iqvia.com |
Stock Details
Ticker Symbol | IQV |
Exchange | NYSE |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001478242 |
CUSIP Number | 46266C105 |
ISIN Number | US46266C1053 |
Employer ID | 27-1341991 |
SIC Code | 8731 |
Key Executives
Name | Position |
---|---|
Ari Bousbib | Chief Executive Officer & Chairman |
Ronald E. Bruehlman | Executive Vice President & Chief Financial Officer |
Dr. Cynthia L. Verst | President of Design & Delivery Innovation |
Dr. Jeffrey A. Spaeder M.D. | Senior Vice President, Global Chief Medical & Scientific Officer |
Eric M. Sherbet J.D. | Executive Vice President, General Counsel & Secretary |
Jim Berkshire | Executive Vice President of Global Technology & Operations |
Keriann Cherofsky | Senior Vice President, Corporate Controller & Chief Accounting Officer |
Kerri Joseph | SVice President of Investment Relation & Treasury |
Trudy Stein | Chief Human Resources Officer & Executive Vice President |
W. Richard Staub III | President of Research & Development Solutions |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 08, 2024 | 4 | Filing |
Nov 08, 2024 | 4 | Filing |
Nov 08, 2024 | 4 | Filing |
Nov 08, 2024 | 4 | Filing |
Oct 31, 2024 | 10-Q | Quarterly Report |
Oct 31, 2024 | 8-K | Current Report |
Aug 29, 2024 | 4 | Filing |
Aug 15, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
Jul 30, 2024 | 4 | Filing |
Jul 30, 2024 | 4 | Filing |